Scientific Programme
The Gastro 2021 Prague (A Joint Meeting WGO/CGS), Prague, Czech Republic, 09/12/2021–11/12/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s).
The final programme as a pdf file (16 MB) is available HERE
All times in the congress programme are in Central European Time – CET (UTC + 1).
9 December 2021 (Thursday)
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | HALL D7 | |
| 08:50–09:00 | Opening Ceremony Chairs: Julius Spicak, Naima Amrani, Ondrej Urban, Guilherme Macedo |
||||
|
Postgraduate Session 1 Chairs: Dan Damitrascu (Romania), Magnus Simren (Sweden) |
GI Oncology: Where Are We Going? Chairs: Matthias Lohr (Sweden), Eric Van Cutsem (Belgium) |
Gut Microbiota in Gastrointestinal Health and Disease Chairs: Francisco Guarner (Spain), Miloslav Kverka (Czech Republic) |
HCV Treatment as the Way to Elimination Chairs: Alessandra Mangia (Italy), Robert Flisiak (Poland) |
||
|
Management of Small Bowel Polyps Fecal Incontinence: Rome IV Criteria and Treatment Critical Issues in Diverticular Disease Management of IBSc and CIC FIT: Is This the Choice in Europe? Q & A live session after each presentation |
Molecular Biology of GI Cancer: What is New? Individualized Therapy of GI Cancer: What is Here and What is to Come? GI Cancer: The Role of Immunotherapy Neoadjuvant Therapy for Operable Cancer: A Paradigm Shift? Novel Molecules, Novel Targets Q & A live session after each presentation |
Current Situation of Microbiota Research Microbiota and Immune System Therapeutic Consequences of IMID in IBD Patients Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection Intestinal Microbiota in IBS Q & A live session after each presentation |
Successful DAA Treatment: DAAs as the Way to Global HCV Elimination Five-year follow-up of cured HCV patients under Real-World Interferon-Free therapy Metabolic Changes in Chronic HCV Infection Improving Quality of Life after DAA Treatment Q & A live session after each presentation |
||
| Coffee break | |||||
9 December 2021 (Thursday) |
|||||
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | HALL D7 | |
|
Postgraduate Session 2 Chairs: Ronnie Fass (USA), David Sanders (UK) |
WDHD SESSION Chairs: Naima Amrani (Morocco), Eamonn Quigley (USA) |
Gut in Motion: News from Upper GI Motility Disorders Chairs: Henriette Heinrich (Switzerland), Zuzana Vackova (Czech Republic) |
Changing Face of Viral Hepatitis Chairs: Cihan Yurdaydin (Turkey), Petr Urbanek (Czech Republic) |
NAFLD/NASH – Compliance and Territorial Aspects Chairs: Peter Jarcuska (Slovakia), Aleksandr V. Nersesov (Kazakhstan) |
|
|
Diagnosis and Management of Functional Chest Pain Improving Neoplasia Detection Rate in Barrett's Esophagus Treatment of HCV in drug users: A rocky road to HCV elimination Current role of endoscopy in bariatric patients management Non-responsive Celiac Disease Q & A live session after each presentation |
Global Issues in the Microbiome from WDHD 2020 Prebiotic and probiotics in gastroenterology and hepatology – when and what? The WGO Guideline updated Hot topics in Obesity from WDHD 2021 The impact of COVID-19 pandemic on patients with obesity Q & A live session after each presentation |
New Discoveries in Pathophysiology of Esophageal and Gastric Motility Diseases How to Diagnose and Classify Esophageal Motility Disorders How to Diagnose Gastroparesis – Scintigraphy, Capsule, Breath Test of Endoflip? Conservative Management of Gastroparesis Endoscopic Treatment for Esophageal and Gastric Motility Disorders Q & A live session after each presentation |
HIV and viral hepatitis: the game changers Current Treatment Options of Hepatitis Delta Infection Current Insight in HBV Reactivation Increasing Burden of HEV Infection Decreasing Risk of HCC after DAA Treatment in HCV Patients Q & A live session after each presentation |
Scoring systems in NAFLD Compliance in NAFLD Management of NAFLD – Territorial Aspects NAFLD patient with elevation of LFTs – case study Q & A live session after each presentation |
|
| Lunch • Industry Satellite Symposium (12:45–13:45, Hall D8+9) | |||||
9 December 2021 (Thursday) |
|||||
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | HALL D7 | |
|
Postgraduate Session 3 Chairs: Nadir Arber (Israel), Jaroslaw Regula (Poland) |
IN CZECH LANGUAGE ONLY CSG Session 1: Liver disease Chairs: Radan Bruha, Petr Urbanek (Czech Republic) |
Early Esophageal Cancer-recent Advances Chairs: Peter Siersema (the Netherlands), Tomas Harustiak (Czech Republic) |
Up-to date Approach to Biliary Stricture Chairs: Ondrej Urban (Czech Republic), Guido Costamagna (Italy) |
||
|
Vaccination in Patients with IBD The New Polish Diagnostic and Therapeutic Recommendations in PDAC Aspirin for everyone? Or for no one Optimizing the Quality of Colorectal Cancer Screening Worldwide Biliary Endoscopy in the Management of Primary Sclerosing Cholangitis and Its Complications Q & A live session after each presentation |
HCC screening HCC prevention Multimodality treatment of CRC liver metastasis Q & A live session after each presentation |
Diagnosis and Staging of Early Esophageal Neoplasia and Premalignant Conditions Indication for Endoscopic Treatment Indication for Surgery Adjuvant Therapy After Endoscopic Treatment of “Advanced” Early Esophageal Carcinoma Q & A live session after each presentation |
Brush and FISH First Cholangioscopy First EUS First Proposal of 2021 Algorithm Stents Q & A live session after each presentation |
|
|
| Coffee break | |||||
9 December 2021 (Thursday) |
|||||
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | HALL D7 | |
|
Postgraduate Session 4 Chairs: Guilherme Macedo (Portugal), Joost Drenth (the Netherlands) |
IN CZECH LANGUAGE ONLY CSG Session 2: Diseases of the pancreas and biliary tract Chairs: Stanislav Rejchrt, Tomas Hucl, Martin Oliverius (Czech Republic) |
Acute Pancreatitis Chairs: Julius Spicak (Czech Republic), Jason Bruce (UK) |
Gut barrier function and GI disease Chairs: Lukas Bajer (Czech Republic), Tim Vanuytsel (Belgium) |
||
|
Endoscopic management of cholecystitis: which patients? Which intervention? Screening in HCC Current treatment Options of Hepatitis Delta Infection Autoimmune Liver Disease Conservative Treatment in Chronic pancreatitis: Any Improvement? Q & A live session after each presentation |
Acute pancreatitis Chronic pancreatitis Biliary tract disease Pancreatic cancer Pancreatobiliary surgery Q & A live session after each presentation |
Pathomechanism of AP: The link between diabetes and severity of disease Etiology, Risk Factors, Genetics Intravenous Fluid Therapy in Acute Pancreatitis: A Critical Review of the Randomized Trials Nutrition and Antibiotics in AP Infected Pancreatic Necrosis: Progress in Interventions Q & A live session after each presentation |
The mucosal barrier: Basic knowledge Barrier function and liver disease The role of increased mucosal permeability in the development of organic and functional gastrointestinal diseases Russian multidisciplinary national consensus “Syndrome of increased epithelial permeability in clinical practice” Q & A live session after each presentation |
|
|
| Welcome cocktail | |||||
10 December 2021 (Friday)
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | ||
|
New Era in IBD Endoscopy Chairs: Thierry Ponchon (France), Zuzana Zelinkova (Slovakia) |
IN CZECH LANGUAGE ONLY CSG Session 3: Gastric cancer – different approaches Chairs: Ilja Tacheci, Jan Martinek, Alexandr Pazdro (Czech Republic) |
Climate Change and Digestive Health Chairs: Naima Amrani (Morocco), Geoffrey Metz (Australia) |
Exploring the border of EUS/ERCP Chairs: Ivan Jovanovic (Serbia), Tibor Gyokeres (Hungary) |
||
|
Novel Endoscopic Techniques for Colorectal Polyps Endoscopic Therapy: Beyond Balloon Dilation Dysplasia Detection Surgical therapy of IBD Q & A live session after each presentation |
Gastric precancerous lesions Early stages of gastric cancer – current practice in GI endoscopy Upper-GI precancerous lesions: surgeon’s view Oncological treatment in early gastric cancer Palliative care in advanced gastric cancer Q & A live session after each presentation |
The Science Controversies and Consensus Implication for Health Current Action Plans Underway Q & A live session after each presentation |
EUS-guided Tissue Acquisition: What is There and What is Next? EUS-guided GEA: Toy or Future? EUS-guided Biliary Drainage: Ready to be Primary? Endoscopic treatment of chronic pancreatitis: when and how State of the art Lecture: Quality in Endoscopy Q & A live session after each presentation |
||
| Coffee break | |||||
10 December 2021 (Friday) |
|||||
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | ||
|
Biologics, Small Molecules, or Back to Conventional Drugs? Chairs: Tim Raine (UK), Zuzana Zelinkova (Slovakia) |
IN CZECH LANGUAGE ONLY CSG Session 4: Functional disorders and food allergies Chairs: Pavel Kohout, Jana Kozeluhova, Jiri Dolina (Czech Republic) |
NAFLD Chairs: Libor Vitek (Czech Republic), Vlad Ratziu (France) |
Miscellaneous Chair: Vivek Kaul (USA) |
||
|
Brief Introduction: Therapeutic Goals in IBD Are Thiopurines Really Out? Therapeutic Drug Monitoring in Current Clinical Practice Medical Management of IBD During Pregnancy and Lactation Nutritional Therapy of IBD Q & A live session after each presentation |
Functional disorders: definition, classification & diagnostic tools Food intolerance a dietary intervention in functional disorders Role of gut microbiota in health and disease Differential diagnostics in organic and functional disorders Q & A live session after each presentation |
NAFLD and Metabolic Syndrome, Global Perspective What do LFT's Tell Us About Prognosis of Metabolic Syndrome? The main risks of a patient with NAFLD and ways to reduce them. The results of the international multicenter study “Success” Current Strategies in NAFLD Therapy Q & A live session after each presentation |
COVID-19 and Endoscopy Multiorgan Transplantation Pancreas transplantation Q & A live session after each presentation |
||
| Lunch • Industry Satellite Symposium in Czech language only (12:30–13:30, Hall D8+9) | |||||
10 December 2021 (Friday) |
|||||
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | ||
|
Colorectal Screening I Chairs: Marcis Leja (Latvia), Nereo Segnan (Italy) |
IN CZECH LANGUAGE ONLY CSG Session 5: Inflammatory bowel disease Chairs: Milan Lukas, Mojmir Kasalicky (Czech Republic) |
What is the Role of Prokinetics in GI Disorders? Chairs: Jan Tack (Belgium), Jan Martinek (Czech Republic) |
Celiac Disease Chairs: David Sander (UK), Kalle Kurppa (Finland) |
||
|
CRC Screening. Typical mistakes when starting a CRC screening program How to Set Up a Successful Screening Program? Slovenian Experience Overview of the Programs in the EU IARC-CANSCREEN Initiative Quality Assurance in Colonoscopy: The Experience of the Polish Screening Program Q & A live session after each presentation |
Treatment strategies and monitoring of clinical response. Is treatment on target beyond the horizon of clinical symptomatology a realistic clinical practice? Biological and innovative therapies. How to achieve the maximum treatment efficiency? Laparoscopic surgery for ulcerative colitis. In which patients and how? Surgical treatment of perianal Crohn's disease. Current state and future perspectives Q & A live session after each presentation |
Should Prokinetics be Given to Patients with Gastro-esophageal Reflux Disease? Do Prokinetics Work in Patients with Functional Dyspepsia? Duodenogastric Reflux – A Disease Requiring Treatment? Case-based discussion Q & A live session after each presentation |
Update on the Diagnosis of Adult Celiac Disease Current Challenges in Pediatric Celiac Disease Extraintestinal Manifestations of Celiac Disease How Should We Monitor Adherence in Celiac Disease? Celiac Disease, Non-Celiac Gluten Sensitivity and IBS – What is the Role of Gluten? Q & A live session after each presentation |
||
| Coffee break | |||||
10 December 2021 (Friday) |
|||||
| HALL D8+9 | HALL D11 | HALL D12 | HALL D3 | ||
|
IN CZECH LANGUAGE ONLY CSG Session 6: Onemocnění dolního GIT Chairs: Premysl Falt, Stepan Suchanek, Julius Orhalmi (Czech Republic) |
H. pylori & Gastric Acid Secretion Chairs: Peter Malfertheiner (Germany), Julius Spicak (Czech Republic) |
Innovation in Endoscopy Chairs: Klaus Monkemuller (Germany), Prateek Sharma (USA) |
|||
|
|
Screening kolorektálního karcinomu – update 2021 Endoskopická léčba kolorektální neoplázie Diagnostika a léčba krvácení do dolní části GIT Nové trendy v kolorektální chirurgii Q & A live session after each presentation |
H. pylori gastritis phenotypes with distinct pattern of gastric acid secretion Management of precancerous conditions and lesions in the stomach The Pro and Cons of HP eradication Impact of acid suppression on gastroentestinal microbiota Q & A live session after each presentation |
Imaging – Virtual Histology? Artificial Intelligence New Devices and European Regulations Single Use Endoscopes Wireless Endoscopy Q & A live session after each presentation |
||
| Industry Satellite Symposium (Hall D8+9) | |||||
11 December 2021 (Saturday)
| HALL D8+9 | HALL D11 | HALL D12 | |||
|
JCG Session Chair: Ronnie Fass (USA) |
Functional Disorders I Chair: Serhat Bor (Turkey) |
Bariatric Endoscopy Chair: Jacques Deviere (Belgium) |
|||
|
State of the art Lecture: Advances in celiac disease testing State of the art Lecture: Hepatic cystic lesions: diagnosis and management in 2020 Q & A live session after each presentation |
Current and Emerging Therapeutic Options for the Management of Functional Dyspepsia New Treatment and Therapeutic Target for IBS Functional Emesis Current Clinical Landscape of Gastroparesis Q & A live session after each presentation |
Endoscopic Treatment of Metabolic Syndrome: The Diabetologists Point of View Novel Endoscopic Therapies in the Treatment of Obesity and Metabolic Syndrome Endoscopic Treatment of Complications After Bariatric Surgery Q & A live session after each presentation |
|
||
| Coffee break | |||||
11 December 2021 (Saturday) |
|||||
| HALL D8+9 | HALL D11 | ||||
|
NAFLD Chairs: Joost Drenth (the Netherlands), Jean-Francois Dufour (Switzerland) |
Functional Disorders II Chairs: Carolina Malagelada (Spain), Heinz Hammer (Austria) |
||||
|
How should we define NASH? Biomarkers in NAFLD liquid biopsy is the future? Endpoints in NASH clinical trials NASH and anti-fibrotic therapies Q & A live session after each presentation |
CIPO and ED: Management of Severe Intestinal Motility Disorders Elimination diets for IBS Efficacy of Intestinal Microbiota Transplantation for the Treatment of Irritable Bowel Syndrome Functional Hearburn Q & A live session after each presentation |
|
|
|
|
